LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Identification of Rickettsial Biomarker Facilitates Early Diagnosis of Tick-borne Spotted Fevers

By LabMedica International staff writers
Posted on 27 Jan 2020
Print article
Image: Photomicrograph of Rickettsia conorii in Vero cells (red rods; magnification ×1,000) (Photo courtesy of Wikimedia Commons)
Image: Photomicrograph of Rickettsia conorii in Vero cells (red rods; magnification ×1,000) (Photo courtesy of Wikimedia Commons)
A protein biomarker has been identified that enables the rapid and specific early diagnosis of tick-borne rickettsial diseases such as Rocky Mountain spotted fever and Mediterranean spotted fever.

The causative agent of these diseases is Rickettsia conorii, a Gram-negative, obligate intracellular bacterium of the genus Rickettsia. It is a member of the spotted fever group and the most geographically dispersed species in the group, recognized in most of the regions bordering on the Mediterranean Sea and Black Sea: Israel, Kenya, and other parts of North, Central, and South Africa, and India.

R. conorii causes the human disease called boutonneuse fever, Mediterranean spotted fever, Israeli tick typhus, Astrakhan spotted fever, Kenya tick typhus, Indian tick typhus, or other names that designate the locality of occurrence while having distinct clinical features. The disease presents as an eschar (dry, dark scab), acute fever, headache, and maculopapular rash. After entering the body, rickettsiae can cause vascular leakage, such as pulmonary or cerebral edema. The prevailing vector is the brown dog tick, Rhipicephalus sanguineus.

Since there are no available tests for diagnosis of early R. conorii infection, Mediterranean spotted fever is often not diagnosed and left untreated, resulting in significant mortality. To address this critical need, investigators at the University of Texas Medical Branch (Galveston, USA) applied a quantitative proteomics approach for analyzing the molecules secreted by primary human umbilical vein endothelial cells that had been infected with R. conorii.

Results revealed that of the 104 proteins whose abundance changed significantly in the R. conorii–infected human umbilical vein endothelial cells’ secretome (the set of proteins expressed by an organism and secreted into the extracellular space), 46 proteins were up-regulated: 45 were host secreted proteins (including cytokines), and one was a rickettsial protein, the putative N-acetylmuramoyl-l-alanine amidase RC0497.

RC0497 is an enzyme that hydrolyzes the link between N-acetylmuramoyl residues and L-amino acid residues in certain cell-wall glycopeptides. Proteins with sequence highly homologous to RC0497 were found to be shared by many species of the spotted fever group rickettsiae, but not typhus group rickettsiae.

The investigators developed an immunoprecipitation (IP) enrichment-selected reaction monitoring (SRM) assay to detect the small amount of circulating RC0497, and this assay was validated as a diagnostic approach in a cohort of humans presenting with acute rickettsial infections.

"The detection of RC0497 has the potential to diagnosis a wide variety of rickettsial spotted fever infections, including Rocky Mountain spotted fever," said senior author Dr. Yingxin Zhao, assistant professor of internal medicine at the University of Texas Medical Branch. "The rickettsioses represent an important unmet need in human and veterinary medicine. Rickettsioses are a spectrum of potentially lethal diseases whose diagnosis and definitive treatment require a high index of suspicion."

The study was published in the January 16, 2020, online edition of the American Journal of Pathology.

Related Links:
University of Texas Medical Branch

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.